Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 103 | 66 | 0 |
| Samples | 70 | 56 | 0 |
| Peptides | 99 | 62 | 0 |
Function
DENND2B · DENN domain containing 2B
This gene was identified by its ability to suppress the tumorigenicity of Hela cells in nude mice. The protein encoded by this gene contains a C-terminal region that shares similarity with the Rab 3 family of small GTP binding proteins. This protein preferentially binds to the SH3 domain of c-Abl kinase, and acts as a regulator of MAPK1/ERK2 kinase, which may contribute to its ability to reduce the tumorigenic phenotype in cells. Three alternatively spliced transcript variants of this gene encoding distinct isoforms are identified. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 96 amino-acid changes on canonical ENST00000313726 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DENND2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DENND2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 1/612 0% |
| Melanoma | 8/210 4% | 2/1899 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Bladder Carcinoma | 2/58 3% | 1/956 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Colorectal Carcinoma | 7/143 5% | 2/3239 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 1/1592 0% |
| Ovarian Carcinoma | 2/109 2% | 0/998 0% |
| Head and Neck Carcinoma | 2/85 2% | 1/1574 0% |
| Gastric Carcinoma | 2/74 3% | 1/1809 0% |
| Other Sarcomas | 1/69 1% | 0/699 0% |
| Esophageal Carcinoma | 1/23 4% | 0/769 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 1/1390 0% |
| Non-Cancerous | 1/104 1% | 0/830 0% |
| Other Blood Cancers | 2/61 3% | 0/2725 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 0/2640 0% |
| Breast Carcinoma | 1/144 1% | 1/3264 0% |
| Other Solid Cancers | 1/94 1% | 0/1515 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| Glioma | 1/52 2% | 0/2127 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 0/2534 0% |
| Hepatocellular Carcinoma | 1/46 2% | 0/2210 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 0/2550 0% |
Mutation Distribution
Where DENND2B is mutated · all tissues, split by cell line vs tissue
How many mutations in DENND2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 103 mutations in DENND2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|